1-7 of 7
Francesca Rancati
Close
Sort by
Journal Articles

High Dose Imatinib Induction Therapy (800 mg/day, 6 Months) In Pre-Treated Chronic Phase CML Patients Improves Cytogenetic and Molecular Responses but Does Not Improve Overall and Progression Free Survival – Final Results of the CELSG Phase III CML11 “ISTAHIT” Trial

Andreas L Petzer, Dominic Fong, Thomas Lion, Irina Dyagil, Zvenyslava Masliak, Andrija Bogdanovic, Laimonas Griskevicius, Sandra Lejniece, Stefan Goranov, Liana Gercheva, Aleksandar Stojanovic, Dontcho Peytchev, Nikolay Tzetkov, Rasa Griniute, Radka Oucheva, Thomas Grubinger, Marthin Kwakkelstein, Francesca Rancati, Günther A Gastl, Dominik Wolf
Journal: Blood
Blood (2010) 116 (21): 2271.
https://doi.org/10.1182/blood.V116.21.2271.2271
Published: 2010
Journal Articles

Outcome and Prognosis of 1955 Patients with Chronic Myeloid Leukemia: First Results of the CML-Registry of the European Treatment and Outcome Study EUTOS.

Joerg Hasford, MD, Gianantonio Rosti, MD, Doris Lindoerfer, Dipl.-Inf., Michele Baccarani, MD, Joelle Guilhot, MSci, Lara Montrucchio, Francesca Rancati, PhD, Bengt Simonsson, MD, Franck Emmanuel Nicolini, MD, PhD, Gert Ossenkoppele, MD, Ruediger Hehlmann, MD
Journal: Blood
Blood (2009) 114 (22): 1109.
https://doi.org/10.1182/blood.V114.22.1109.1109
Published: 2009
Journal Articles

The European Treatment and Outcome Study (EUTOS) for Chronic Myeloid Leukemia (CML). A Prospective, Population-Based European Registry.

Michele Baccarani, Bengt Simonsson, Doris Lindörfer, Gianantonio Rosti, Antonio M Almeida, MD, PhD, Andrija Bogdanovic, Richard E. Clark, Adriana Colita, Paul A. Costeas, Laimonas Griskevicius, Joelle Guilhot, Andrzej Hellmann, MD, PhD, DSc, Karel Indrak, MD, PhD, Edward Laane, Boris Labar, MD, PhD, Tamas Masszi, MD, Sandra Lejniece, MD, Jiri Mayer, MD, Gert Ossenkoppele, Panayiotis Panayiotidis, Kimmo Porkka, MD, PhD, Susanne Saussele, Andreas Hochhaus, MD, Juan Luis Steegmann, MD, PhD, Josef Thaler, MD, Anna Turkina, Gregor Verhoef, Andrey Zaritskey, Irena Preloznik Zupan, Francesca Rancati, Lara Montrucchio, Rüdiger Hehlmann, Joerg Hasford
Journal: Blood
Blood (2009) 114 (22): 4272.
https://doi.org/10.1182/blood.V114.22.4272.4272
Published: 2009
Journal Articles

Imatinib High Dose (800 mg): Results of a Phase II Trial of the GIMEMA (Gruppo Italiano Malattie Ematologiche Dell’Adulto) CML Working Party in Intermediate Sokal Risk Patients and Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients.

Gianantonio Rosti, MD, Fausto Castagnetti, MD, Marilina Amabile, BD, Nicoletta Testoni, BD, Angela Poerio, BD, Giulia Marzocchi, BD, Massimo Breccia, MD, Francesca Palandri, MD, Tamara Intermesoli, MD, Fabio Stagno, MD, Giorgina Specchia, MD, Elisabetta Abruzzese, MD, Panagiota Giannoulia, MD, Giuseppe Saglio, MD, Fabrizio Pane, MD, Francesca Rancati, BD, Arnon Nagler, MD, Ibrahim Haznedaroglu, MD, Kimmo PorkKa, MD, Henrik Hjorth-Hansen, MD, Johan L. Nielsen, MD, Bengt Simonsson, MD, Giovanni Martinelli, MD, Michele Baccarani, MD
Journal: Blood
Blood (2006) 108 (11): 4776.
https://doi.org/10.1182/blood.V108.11.4776.4776
Published: 2006
Journal Articles

Imatinib Mesylate Can Induce Molecular Complete Remission in Idiopathic Hypereosinophilic Syndrome (HES). A Phase II Multicentric Italian Clinical Trial.

Giovanni Martinelli, Daniela Cilloni, Michela Rondoni, Francesca Messa, Emanuela Ottaviani, Enrico Gottardi, Pier Paolo Piccaluga, Michele Malagola, Simona Soverini, Serena Merante, Giuliana Alimena, Costanza Bosi, Antonio De Vivo, Gianantonio Rosti, Emilia Giugliano, Fabrizio Pane, Barbara Izzo, Nicoletta Testoni, Stefania Paolini, Francesca Rancati, Renato Bassan, Cristina Mecucci, Michele Baccarani, Giuseppe Saglio
Journal: Blood
Blood (2005) 106 (11): 375.
https://doi.org/10.1182/blood.V106.11.375.375
Published: 2005
Journal Articles

Time- and Dose-Response Relationships of Imatinib Mesylate (Glivec) Therapy for Chronic Hypereosinophilic Syndromes.

Renato Bassan, MD, Sara Acerboni, BSc, Silvia Mappa, MD, Piera Viero, MD, Federica Delaini, BSc, Giuseppe Rossi, Valentina Rossi, A. Vannucchi, MD, Eros Di Bona, MD, Emanuela Ruggeri, Anna Salvi, Ursula Giussani, BSc, Francesca Rancati, MD, Tamara Intermesoli, MD, Alessandro Rambaldi, MD, Tiziano Barbui, MD
Journal: Blood
Blood (2005) 106 (11): 2596.
https://doi.org/10.1182/blood.V106.11.2596.2596
Published: 2005
Journal Articles

Imatinib mesylate in the treatment of c-kit–positive acute myeloid leukemia: is this the real target?

Michele Malagola, Giovanni Martinelli, Michela Rondoni, Stefania Paolini, Stavrula Gaitani, Mario Arpinati, Pier Paolo Piccaluga, Marilina Amabile, Constanza Basi, Emanuela Ottaviani, Anna Candoni, Enrico Gottardi, Daniela Cilloni, Monica Bocchia, Giuseppe Saglio, Francesco Lauria, Renato Fanin, Giuseppe Visani, Maria Carla Marrè, Michela Maderna, Francesca Rancati, Vincenza Vinaccia, Domenico Russo, Michele Baccarani
Journal: Blood
Blood (2005) 105 (2): 904–905.
https://doi.org/10.1182/blood-2004-08-3088
Published: 2005